Evidence map›Paper›PMID 34578859›Full record

ArticleNutrients2021

Bovine Colostrum Supplementation Improves Bone Metabolism in an Osteoporosis-Induced Animal Model.

Eirini K Kydonaki, Laura Freitas, Bruno M Fonseca, Henrique Reguengo, Carlos Raposo Simón, Ana R Bastos, Emanuel M Fernandes, Raphaël F Canadas, Joaquim Miguel Oliveira, Vitor M Correlo and 9 more

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 5 countries.

Eirini K KydonakiUCIBIO/REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0001-7320-212X
Laura FreitasUCIBIO/REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0001-6758-4520
Bruno M FonsecaUCIBIO/REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0002-8873-5591
Henrique ReguengoUCIBIO/REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0002-0246-6790
Carlos Raposo SimónSALURIS, 28108 Madrid, Spain.ORCID 0000-0002-4817-761X
Ana R Bastos3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Guimarães, Portugal.
Emanuel M Fernandes3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Guimarães, Portugal.ORCID 0000-0002-4296-2529
Raphaël F Canadas3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Guimarães, Portugal.
Joaquim Miguel Oliveira3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Guimarães, Portugal.ORCID 0000-0001-7052-8837
Vitor M Correlo3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Guimarães, Portugal.ORCID 0000-0002-5516-7583
Rui L Reis3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Guimarães, Portugal.
Maria VlioraSchool of Sports and Exercise Sciences, University of Thessaly, 42100 Trikala, Greece.ORCID 0000-0002-1884-1057
Parakevi GkiataSchool of Sports and Exercise Sciences, University of Thessaly, 42100 Trikala, Greece.
Yiannis KoutedakisSchool of Sports and Exercise Sciences, University of Thessaly, 42100 Trikala, Greece.ORCID 0000-0002-7065-9447
Georgia NtinaBME, Biomechanical Solutions, 43150 Karditsa, Greece.
Rui PintoiMed.UL, Faculty of Pharmacy, University of Lisbon, 1649-003 Lisbon, Portugal.ORCID 0000-0002-1667-7871
Andres E CarrilloDepartment of Exercise Science, Chatham University, Pittsburgh, PA 15232, USA.ORCID 0000-0002-2293-079X
Franklim MarquesUCIBIO/REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Tânia AmorimUCIBIO/REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Universidade do Porto · PTUniversity of Minho · PTUniversity of Thessaly · GRChatham University · USUniversidad Complutense de Madrid · ESUniversity of Lisbon · PTUniversity of Wolverhampton · GB

Funding

MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) grant funded by the European Union 778277
6 · The paper itself

Abstract

Osteoporosis is characterized by bone loss. The present study aims to investigate the effects of bovine colostrum (BC) on bone metabolism using ovariectomized (OVX) and orchidectomized (ORX) rat models. Twenty-seven-week-old Wistar Han rats were randomly assigned as: (1) placebo control, (2) BC supplementation dose 1 (BC1: 0.5 g/day/OVX, 1 g/day/ORX), (3) BC supplementation dose 2 (BC2: 1 g/day/OVX, 1.5 g/day/ORX) and (4) BC supplementation dose 3 (BC3: 1.5 g/day/OVX, 2 g/day/ORX). Bone microarchitecture, strength, gene expression of VEGFA, FGF2, RANKL, RANK and OPG, and bone resorption/formation markers were assessed after four months of BC supplementation. Compared to the placebo, OVX rats in the BC1 group exhibited significantly higher cortical bone mineral content and trabecular bone mineral content (

Indexed as

AnimalsBone and BonesBone DensityCattleColostrumDietary SupplementsDisease Models, AnimalFemaleOsteoporosisOvariectomyRatsRats, Wistarbonebovine colostrumosteoporosissupplementation

Identifiers

PMID34578859
PMCPMC8471956
OpenAlexW3198654521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.